Police & Firemen s Retirement System of New Jersey Increases Stake in Elanco Animal Health Incorporated $ELAN

Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 6.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 189,508 shares of the company’s stock after purchasing an additional 11,556 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Elanco Animal Health were worth $2,706,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. First Horizon Advisors Inc. lifted its stake in shares of Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after buying an additional 2,414 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Elanco Animal Health by 261.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock valued at $58,000 after acquiring an additional 2,922 shares during the last quarter. Wealthquest Corp purchased a new position in Elanco Animal Health in the 1st quarter worth approximately $56,000. Parallel Advisors LLC boosted its holdings in shares of Elanco Animal Health by 66.6% during the 2nd quarter. Parallel Advisors LLC now owns 6,432 shares of the company’s stock worth $92,000 after purchasing an additional 2,572 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in shares of Elanco Animal Health by 198.9% during the 2nd quarter. Allworth Financial LP now owns 7,035 shares of the company’s stock worth $100,000 after purchasing an additional 4,681 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ELAN. Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. UBS Group lifted their price target on Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a report on Thursday, November 13th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. Finally, Stifel Nicolaus boosted their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

Elanco Animal Health Stock Down 0.2%

Shares of ELAN opened at $21.39 on Wednesday. The company’s 50-day moving average price is $20.68 and its 200 day moving average price is $16.87. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $23.09. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The firm has a market cap of $10.63 billion, a P/E ratio of 356.48, a price-to-earnings-growth ratio of 2.91 and a beta of 1.71.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.